Figure 11 | Gene Therapy

Figure 11

From: A new plasmid-based microRNA inhibitor system that inhibits microRNA families in transgenic mice and cells: a potential new therapeutic reagent

Figure 11

miR expression levels in PMIS-miR-17-18, PMIS-miR-19-92 and PMIS-miR-17-18-19-92 TG mice. (a) Total RNA was harvested from E18.5 mice heads and subjected to miR expression analyses as per the manufacturer's instruction (Qiagen, Hilden, Germany). miR expression is calculated as ΔΔCT after normalization to control primers. All data was compared with WT mice (N=2, two different mice and qPCR performed in triplicate for each mouse; *P<0.05). (b) Northern blot analyses of miR-19 and miR-17 expression in total RNA harvested from E18.5 mouse mandibles. PMIS-miR-17-18 mice demonstrated reduce miR-17; PMIS-miR-19-92 mice showed reduced miR-19 and the PMIS-miR-17-18-19-92 mice had reduced expression of both miR-17 and 19. (c) qPCR of Ndrg3, Bckdk and Cd320 transcripts in total RNA isolated from PMIS-miR-17-18-19-92, PMIS-miR-200a or WT E18.5 mouse liver (N=2). (d) miR expression in RNA isolated from PMIS-miR-17-18-19-92, PMIS-miR-200a or WT E18.5 mouse liver.

Back to article page